The identification of a CD47-blocking “hotspot” and design of a CD47/PD-L1 dual-specific antibody with limited hemagglutination
Open Access
- 6 March 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-3
- https://doi.org/10.1038/s41392-020-0121-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's LymphomaThe New England Journal of Medicine, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenThe New England Journal of Medicine, 2018
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of Clinical Oncology, 2017
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumorsNature Medicine, 2015
- A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cellsmAbs, 2015
- Macrophages are critical effectors of antibody therapies for cancermAbs, 2015
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsProceedings of the National Academy of Sciences of the United States of America, 2012
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47Molecular Cell, 2008